1. Landis S, Murray T, Bolden S, et al.: Cancer Statistics 1999. CA Cancer J Clin 1999, 49:8–31.
2. Pecorelli S, Odicino F, Maisonneuve P: Carcinoma of the Ovary. In FIGO Annual Report on the Results of Treatment in Gynecological Cancer, Vol 23. Edited by Pecorelli S, Creasman WT. Oxford: Isis Medical Media Limited; 1998.
3. Chi D, Hoskins WJ: Primary surgical management of advanced epithelial ovarian cancer. In Ovarian Cancer, edn 2. Edited by Rubin SC, Sutton GP. Philadelphia: Lippincott, Williams & Wilkins, in press.
4. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1–6. Pivotal trial showing the survival advantage for the addition of paclitaxel to the primary treatment regimen.
5. DuBois A, Lueck HJ, Meier W, et al.: Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: an update of an Arbeitsgemeinschaft Gynaekologische Oncologie (AGO) Study Group Trial. Proc ASCO 1999, 18:356(a). Study suggesting the equivalence of carboplatin and cisplatin with less toxicity in the former.